Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338842 | 0.89 | CYP19A1 (0.41) | CA2CA1CA9CA12CA3 | |
| SCHEMBL17338844 | 0.89 | CYP19A1 (0.41) | CA2CA1CA9CA12CA3 | |
| SCHEMBL17338892 | 0.82 | PARP15 (0.43) | CA2CA1CA9PARP15PARP10 | |
| SCHEMBL17338893 | 0.82 | PARP15 (0.43) | CA2CA1CA9PARP15PARP10 | |
| SCHEMBL1305151 | 0.80 | NOS3 (0.53) | CA2CA1CA9CA12CA3 | |
| SCHEMBL4947766 | 0.73 | NOS3 (0.50) | CA2CA1CA9CA12CA3 | |
| SCHEMBL1160894 | 0.73 | NOS3 (0.50) | CA2CA1CA9CA12CA3 | |
| SCHEMBL14378467 | 0.72 | ABCC9 (0.50) | CA2CA1CA9CA12CA3 | |
| SCHEMBL4078022 | 0.72 | CA2 (0.58) | CA2CA1CA9CA12CA3 | |
| SCHEMBL21783612 | 0.72 | CA2 (0.58) | CA2CA1CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154941-B1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2021-01-20 | — | — | EP | disclosed |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ALLOCYTE PHARMACEUTICALS AG (CH) | 2018-09-18 | — | — | US | disclosed |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| EP-3154941-A1 | SMALL MOLECULE LFA-1 INHIBITORS | AlloCyte Pharmaceuticals AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189265-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2015-12-17 | — | — | WO | disclosed |
| WO-2010146391-A1 | REGIOSELECTIVE SYNTHESIS OF LETROZOLE | GENERICS [UK] LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ICAM1, VCAM1, ITGB1 | CA2 3924/4885CA1 3060/4885CA9 3887/4885 |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | CA2 3924/4885CA1 3060/4885CA9 3887/4885 |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | CA2 3924/4885CA1 3060/4885CA9 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.